Assessment of monoclonal gammopathies

Last reviewed: 6 Sep 2022
Last updated: 31 Mar 2022

Summary

Differentials

Common

  • Monoclonal gammopathy of undetermined significance
  • Chronic lymphocytic leukaemia
  • Non-Hodgkin's lymphoma
Full details

Uncommon

  • Light chain deposition disease
  • Post-transplant monoclonal gammopathies
  • Multiple myeloma
  • Plasma cell leukaemia
  • Waldenstrom's macroglobulinaemia
  • Solitary plasmacytoma
  • POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes)
  • Hepatitis C
  • HIV infection
  • Primary amyloidosis
  • Cryoglobulinaemia
  • Systemic lupus erythematosus (SLE)
  • Rheumatoid arthritis
  • Psoriatic arthritis
  • Sjogren syndrome
  • Schnitzler syndrome
Full details

Contributors

Authors

Shaji Kumar, MD

Mark and Judy Mullins Professor of Hematological Malignancies

Division of Hematology

Mayo Clinic

Rochester

MN

Disclosures

SK has received research funding for clinical trials for his institution from: Abbvie, Amgen, BMS, Carsgen, Janssen, KITE, Merck, Astra-Zeneca, Novartis, Roche-Genentech, Takeda, and Tenebio. SK has participated in consulting and advisory boards (with no personal payment) for Abbvie, Amgen, BMS, Janssen, Roche-Genentech, Takeda, KITE, Astra-Zeneca, Bluebird Bio, and (with personal payment) Oncopeptides, Beigene, and Antengene.

Peer reviewers

Antonio Palumbo, MD

Associate Professor

University of Turin

Chief

Myeloma Unit

Ospedale Molinette

Turin

Italy

Disclosures

AP declares that he has no competing interests.

John R. Wingard, MD

Price Eminent Scholar and Professor of Medicine Director

Bone Marrow Transplant Program

Division of Hematology and Oncology

University of Florida College of Medicine

Gainesville

FL

Disclosures

JRW declares that he has no competing interests.

John Densmore, MD, PhD

Associate Professor of Clinical Medicine

Department of Medicine

Division of Hematology/Oncology

University of Virginia

Charlottesville

VA

Disclosures

JD declares that he has no competing interests.

  • Assessment of monoclonal gammopathies images
  • Guidelines

    • Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management
    • Guidelines for the investigation of newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance (MGUS)
    Guidelines
  • Patient leaflets

    Hepatitis C: what is it?

    Monoclonal gammopathy of undetermined significance

    More Patient leaflets
  • padlock-lockedLog in or subscribe to access all of BMJ Best Practice

Use of this content is subject to our disclaimer